الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

pharmsure veterinary products europe ltd - mycoplasma synoviae stofn ms-h - Ónæmislyf fyrir aves, lifandi bakteríu bóluefni - kjúklingur - fyrir virk bólusetningar framtíð með neitt grill ræktanda hænur, framtíð lag ræktanda hænur og framtíð lag hænur til að draga úr lofti sac sár og fækka egg með óeðlilega skel myndun af völdum r synoviae.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

gsk vaccines s.r.l. - ytri himnu frá neisseria meningitidis hópur b (álag nýja-sjáland 98/254), skal læknir hafa neisseria meningitidis hópur b fhbp samruna prótín, skal læknir hafa neisseria meningitidis hópur b nada prótín, skal læknir hafa neisseria meningitidis hópur b nhba samruna prótín - meningitis, meningococcal - meningókokka bóluefni - virkt ónæmisaðgerðir gegn innrásarsjúkdómum af völdum neisseria meningitidis serogroup-b stofnanna.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningókokka hóp a, c, w-135 og y samtengd bóluefni - immunization; meningitis, meningococcal - bakteríubóluefni - vialsmenveo er ætlað fyrir virk bólusetningar sem börn (frá tveggja ára aldri), unglingum og fullorðnir í hættu af völdum neisseria meningitidis tekur, c, w135 og y, til að koma í veg fyrir innrásar sjúkdómur. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - bóluefni - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

vbi vaccines b.v. - lifrarbólga b yfirborðs mótefnavaka - lifrarbólga b - bóluefni - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

cz vaccines, s.a.u. - mycobacterium paratuberculosis, inactivated strain 316 f - stungulyf, fleyti - ≥ 2 mm itt avian ppd

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

mcm vaccine b.v. - barnaveiki toxoid, stífkrampamótefnavaka, bordetella stífkrampa berast: stífkrampa toxoid, þráðlaga haemagglutinin, pertactin, fimbriae gerðir 2 og 3, lifrarbólgu b yfirborðið antigen framleitt í ger frumur, poliovirus (óvirkt): tegund 1 (mahoney), tegund 2 (mef-1), gerð 3 (saukett) framleitt í vero frumur/ haemophilus influenzae gerð b fjölsykra (polyribosylribitol fosfórinn) samtengdum til að þvag prótín. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - bóluefni - vaxelis (dtap-hb-ipv-hib) er ætlað fyrir aðal og orku bólusetningu í börnum og smábörn frá aldri 6 vikur, gegn barnaveiki, stífkrampa, stífkrampa, lifrarbólgu b, mænusótt og innrásar sjúkdóma sem orsakast af haemophilus influenzae gerð b (hib). notkun vaxelis ætti að vera í samræmi við opinberar ráðleggingar.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - bóluefni - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.